Leerink Partnrs Cuts Earnings Estimates for BridgeBio Pharma

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Investment analysts at Leerink Partnrs cut their Q3 2025 EPS estimates for BridgeBio Pharma in a report issued on Monday, June 30th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($0.79) per share for the quarter, down from their previous estimate of ($0.78). The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.87) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at $0.66 EPS, FY2028 earnings at $3.50 EPS and FY2029 earnings at $5.52 EPS.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.12. The business had revenue of $36.74 million during the quarter, compared to the consensus estimate of $57.14 million. BridgeBio Pharma’s revenue was down 44.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.20) earnings per share.

Several other brokerages have also issued reports on BBIO. HC Wainwright upped their target price on shares of BridgeBio Pharma from $53.00 to $56.00 and gave the stock a “buy” rating in a research report on Monday, June 9th. Wolfe Research initiated coverage on shares of BridgeBio Pharma in a research note on Tuesday, June 17th. They issued an “outperform” rating and a $49.00 price objective for the company. JPMorgan Chase & Co. lifted their target price on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the stock an “overweight” rating in a research report on Monday, March 24th. Bank of America boosted their price target on shares of BridgeBio Pharma from $50.00 to $54.00 and gave the stock a “buy” rating in a research note on Wednesday, June 25th. Finally, Redburn Atlantic assumed coverage on shares of BridgeBio Pharma in a research report on Monday, March 31st. They set a “buy” rating and a $50.00 price target for the company. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $58.85.

BridgeBio Pharma Trading Up 2.0%

BBIO stock opened at $43.71 on Thursday. The company’s 50 day moving average is $37.78 and its 200 day moving average is $34.52. The stock has a market cap of $8.30 billion, a price-to-earnings ratio of -12.38 and a beta of 1.15. BridgeBio Pharma has a 1-year low of $21.72 and a 1-year high of $45.48.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BBIO. Steward Partners Investment Advisory LLC increased its stake in shares of BridgeBio Pharma by 85.8% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock worth $28,000 after acquiring an additional 472 shares in the last quarter. GAMMA Investing LLC raised its stake in BridgeBio Pharma by 71.0% during the first quarter. GAMMA Investing LLC now owns 920 shares of the company’s stock valued at $32,000 after buying an additional 382 shares during the last quarter. Jones Financial Companies Lllp purchased a new stake in shares of BridgeBio Pharma in the first quarter worth $35,000. Itau Unibanco Holding S.A. purchased a new position in shares of BridgeBio Pharma in the 4th quarter worth about $41,000. Finally, Sterling Capital Management LLC grew its position in BridgeBio Pharma by 554.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,787 shares of the company’s stock valued at $49,000 after purchasing an additional 1,514 shares during the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Neil Kumar sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $42.54, for a total transaction of $1,701,600.00. Following the completion of the transaction, the chief executive officer owned 975,686 shares in the company, valued at $41,505,682.44. This represents a 3.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Global Investors Lp Viking sold 3,500,000 shares of the business’s stock in a transaction on Friday, June 27th. The shares were sold at an average price of $44.00, for a total transaction of $154,000,000.00. Following the transaction, the insider directly owned 18,555,375 shares in the company, valued at approximately $816,436,500. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 9,936,181 shares of company stock worth $375,878,164. Insiders own 18.20% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.